Download MendeleyDesign and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK.
Hom, R.K., Bowers, S., Sealy, J.M., Truong, A.P., Probst, G.D., Neitzel, M.L., Neitz, R.J., Fang, L., Brogley, L., Wu, J., Konradi, A.W., Sham, H.L., Toth, G., Pan, H., Yao, N., Artis, D.R., Quinn, K., Sauer, J.M., Powell, K., Ren, Z., Bard, F., Yednock, T.A., Griswold-Prenner, I.(2010) Bioorg Med Chem Lett 20: 7303-7307
- PubMed: 21071223
- DOI: https://doi.org/10.1016/j.bmcl.2010.10.066
- Primary Citation of Related Structures:
3OXI - PubMed Abstract:
From high throughput screening, we discovered compound 1, the prototype for a series of disubstituted thiophene inhibitors of JNK which is selective towards closely related MAP kinases p38 and Erk2. Herein we describe the evolution of these compounds to a novel class of thiophene and thiazole JNK inhibitors that retain favorable solubility, permeability, and P-gp properties for development as CNS agents for treatment of neurodegeneration. Compound 61 demonstrated JNK3 IC(50)=77 nM and retained the excellent broad kinase selectivity observed for the series.
Organizational Affiliation:
Department of Chemical Sciences, Elan Pharmaceuticals, South San Francisco, CA 94080, USA. roy.hom@elan.com
